axl-targeting adc adct-601 (ADC Therapeutics)
90
Structured Review
ADC Therapeutics
axl-targeting adc adct-601
Axl Targeting Adc Adct 601, supplied by ADC Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adct-601/adct+601/pmc12187457-55-0-11
Average 90 stars, based on 1 article reviews
Axl Targeting Adc Adct 601, supplied by ADC Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adct-601/adct+601/pmc12187457-55-0-11
Average 90 stars, based on 1 article reviews
axl-targeting adc adct-601 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Conjugation Assay:Article Title: Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Article Snippet: Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer.. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early.. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. Article Title: Click Chemistry Conjugations Article Snippet: Site-specific ADCs conjugated via CuAAC and SPAAC have both been demonstrated [ 31 – 37 ] and some of them are currently under clinical evaluation (e.g. STRO-001 from Sutro Article Title: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity? Article Snippet: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?. Paul J.M.. Jackson, Syafiq Kay, Ilona Pysz, David E. Thurston* Femtogenix Ltd., Biopark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom Institute for Pharmaceutical Science, King’s College London, Faculty of Life Sciences and Medicine, Franklin Wilkins Building, London SE1 9NH, United Kingdom Drug Discovery Today: Technologies Vol. Article Title: Site-specific conjugation of native antibody Article Snippet: Glycan remodeling , Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: In addition to Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Glycoproteomics:Article Title: Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Article Snippet: Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer.. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early.. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. Article Title: Click Chemistry Conjugations Article Snippet: Site-specific ADCs conjugated via CuAAC and SPAAC have both been demonstrated [ 31 – 37 ] and some of them are currently under clinical evaluation (e.g. STRO-001 from Sutro Article Title: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity? Article Snippet: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?. Paul J.M.. Jackson, Syafiq Kay, Ilona Pysz, David E. Thurston* Femtogenix Ltd., Biopark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom Institute for Pharmaceutical Science, King’s College London, Faculty of Life Sciences and Medicine, Franklin Wilkins Building, London SE1 9NH, United Kingdom Drug Discovery Today: Technologies Vol. Article Title: Site-specific conjugation of native antibody Article Snippet: Glycan remodeling , Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: In addition to Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Clinical Proteomics:Article Title: Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Article Snippet: Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer.. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early.. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. Article Title: Click Chemistry Conjugations Article Snippet: Site-specific ADCs conjugated via CuAAC and SPAAC have both been demonstrated [ 31 – 37 ] and some of them are currently under clinical evaluation (e.g. STRO-001 from Sutro Article Title: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity? Article Snippet: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?. Paul J.M.. Jackson, Syafiq Kay, Ilona Pysz, David E. Thurston* Femtogenix Ltd., Biopark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom Institute for Pharmaceutical Science, King’s College London, Faculty of Life Sciences and Medicine, Franklin Wilkins Building, London SE1 9NH, United Kingdom Drug Discovery Today: Technologies Vol. Article Title: Site-specific conjugation of native antibody Article Snippet: Glycan remodeling , Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: In addition to Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Mutagenesis:Article Title: Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Article Snippet: Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer.. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early.. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. Article Title: Click Chemistry Conjugations Article Snippet: Site-specific ADCs conjugated via CuAAC and SPAAC have both been demonstrated [ 31 – 37 ] and some of them are currently under clinical evaluation (e.g. STRO-001 from Sutro Article Title: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity? Article Snippet: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?. Paul J.M.. Jackson, Syafiq Kay, Ilona Pysz, David E. Thurston* Femtogenix Ltd., Biopark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom Institute for Pharmaceutical Science, King’s College London, Faculty of Life Sciences and Medicine, Franklin Wilkins Building, London SE1 9NH, United Kingdom Drug Discovery Today: Technologies Vol. Article Title: Site-specific conjugation of native antibody Article Snippet: Glycan remodeling , Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: In addition to Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Modification:Article Title: Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Article Snippet: Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer.. However, despite more than 20 years of clinical development, only four ADC have reached market approval, while at least 50 clinical programs were terminated early.. The high attrition rate of ADCs may, at least in part, be attributed to heterogeneity and instability of conventional technologies. Article Title: Click Chemistry Conjugations Article Snippet: Site-specific ADCs conjugated via CuAAC and SPAAC have both been demonstrated [ 31 – 37 ] and some of them are currently under clinical evaluation (e.g. STRO-001 from Sutro Article Title: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity? Article Snippet: Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?. Paul J.M.. Jackson, Syafiq Kay, Ilona Pysz, David E. Thurston* Femtogenix Ltd., Biopark, Broadwater Road, Welwyn Garden City AL7 3AX, United Kingdom Institute for Pharmaceutical Science, King’s College London, Faculty of Life Sciences and Medicine, Franklin Wilkins Building, London SE1 9NH, United Kingdom Drug Discovery Today: Technologies Vol. Article Title: Site-specific conjugation of native antibody Article Snippet: Glycan remodeling , Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: In addition to Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: Article Title: Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates Article Snippet: |